| ECHELON-2研究：Brentuximab Vedotin联合CHP方案一线治疗CD30表达阳性的外周T细胞淋巴瘤的疗效分析 |
| |
| 引用本文： | 杨春丽,邹立群.ECHELON-2研究：Brentuximab Vedotin联合CHP方案一线治疗CD30表达阳性的外周T细胞淋巴瘤的疗效分析[J].循证医学,2020,20(2):85-88. |
| |
| 作者姓名： | 杨春丽 邹立群 |
| |
| 作者单位： | 四川大学华西医院肿瘤科, 成都 610041 |
| |
| 摘 要： |
|
| 关 键 词： | A+CHP方案 外周T细胞淋巴瘤 |
ECHELON-2 Study： Curative Effect Analysis of Brentuximab Vedotin with CHP Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma |
| |
| Reviewers：YANG Chun-li,ZOU Li-qun.ECHELON-2 Study： Curative Effect Analysis of Brentuximab Vedotin with CHP Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma[J].The Journal of Evidence-Based Medicine,2020,20(2):85-88. |
| |
| Authors: | Reviewers：YANG Chun-li ZOU Li-qun |
| |
| Institution: | Reviewers'address：Department of Oncology,West China Hospital of Sichuan University, Chengdu 610041, China |
| |
| Abstract: | |
| |
| Keywords: | A + CHP peripheral T cell lymphoma |
|
| 点击此处可从《循证医学》浏览原始摘要信息 |
| 点击此处可从《循证医学》下载免费的PDF全文 |
|
